n-Lorem Foundation Identifies New, Important Roles of JIP3, Offering Critical Insights into Therapeutic Approaches for Nano-rare Patients
n-Lorem, a nonprofit foundation, announced today the publication of new research characterizing a nano-rare mutation in a gene that is pivotal to normal cell signaling and cellular homeostasis. The mitogen-activated protein kinase 8 interacting protein 3 ( MAPK8IP3 ) gene encodes for c-Jun N-terminal kinase-interacting (JNK-interacting) protein 3 (JIP3). Mutations in the MAPK8IP3 gene have been linked to severe neurodevelopmental disorders, however, the mechanisms of JIP3 underlying these deleterious effects were poorly understood. In this publication, n-Lorem scientists identified several significant roles JIP3 could play in the body, characterized a mutation in MAPK8IP3 and identified a path forward to use antisense oligonucleotide (ASO) medicines to address mutations in the MAPK8IP3 gene. The study, authored by n-Lorem scientist Wei Zhang, et al was published today in JCI Insights ( JCI Insight. 2025; 10(8):e187199).
'The work described in this manuscript is exemplary of some of the challenges in defining a therapeutic strategy for nano-rare patients who have de novo mutations in genes,' said Stanley Crooke, M.D., Ph.D., Chairman, Founder and CEO of n-Lorem. 'As is often the case, the nature of the MAPK8IP3 mutation, whether loss-of-function or toxic gain-of-function, was not clearly proven before we started this. Since ASOs can be designed to carry out a variety of actions, we must know at the onset of the program if we need to alter mRNA splicing or increase or decrease protein expression. Additionally, it is often unclear what the proximal molecular events are. This information is essential to know if we are likely to correct the phenotype and potentially improve the condition.'
'At The Wolverine Foundation, our focus is to turn cutting-edge science into tangible hope for the children affected by MAPK8IP3-related neurodevelopmental disorders,' said Amy McCooe, Executive Director of The Wolverine Foundation. 'The study published in JCI Insight points to antisense oligonucleotides as a promising avenue worth pursuing. Although much remains to be learned about the therapeutic potential of this approach, we are encouraged by these findings and grateful to n-Lorem's scientists for moving us a meaningful step forward.'
The study, titled 'A toxin gain-of-function variant in MAPK8IP3 provides insights into JIP3 cellular roles,' investigated a patient with a missense mutation in the MAPK8IP3 gene (c. 1714 C > T, Arg578Cys) linked to dystonia, gross motor dysfunction and developmental delays. Aimed at uncovering the molecular mechanisms driving the cytotoxicity of MAPK8IP3 mutations the research sheds new light on the cellular functions of JIP3 and its role in neurodevelopmental disorders. The study revealed, for the first time, that the Arg578Cys mutation in JIP3 was shown to trigger cellular abnormalities that culminate in cell death and neurodegenerative disease in patients with this mutation. Funded by the Wolverine Foundation, the study also revealed that this toxic gain-of-function variant disrupts JIP3's molecular interactions, selectively impairing dopamine receptor 1 signaling while sparing dopamine receptor 2 pathways. Since disruptions in dopamine signaling are closely linked to movement disorders like Parkinson's disease, these findings may explain the motor symptoms observed in the patient.
'The significance of JIP3 has been unfolding over the last few years, but a comprehensive understanding of its functioning has been incomplete,' Crooke said. 'This research has offered us new insight into the role of JIP3 and how mutations in the protein can contribute to neurodegenerative disorders. This work could not have been completed without support from the Wolverine Foundation, and we want to thank them for their confidence and patience as we embarked on this work together.'
The Wolverine Foundation is dedicated to advancing research and discover novel therapeutic approaches to treat the neuro-developmental disease caused by genetic variations in the gene MAPK8IP3. The organization investigates disease mechanisms and encourages scientific collaboration between academic research, drug discovery and clinical development.
About n-Lorem
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem received over 330 applications for treatment with more than 160 nano-rare patients approved and more than 25 patients on active treatment. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.
To learn more about n-Lorem's mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250508847067/en/
CONTACT: n-Lorem Contact:
Amy Williford, Ph.D.
Executive Director of Communications
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH HEALTH GENETICS PHILANTHROPY FOUNDATION OTHER HEALTH
SOURCE: n-Lorem Foundation
Copyright Business Wire 2025.
PUB: 05/08/2025 09:05 AM/DISC: 05/08/2025 09:05 AM
http://www.businesswire.com/news/home/20250508847067/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Sarepta Therapeutics Provides Statement on ELEVIDYS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Shortly after 2:30 p.m. ET today, Sarepta received an informal request from the U.S. Food and Drug Administration (FDA) to voluntarily halt shipment of ELEVIDYS (delandistrogene moxeparvovec), our gene therapy for Duchenne muscular dystrophy (Duchenne), in the U.S. We first heard of this potential request earlier in the day at the same time the public and our patient communities did, through media reports. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies. This guides every decision we make, as evidenced by our conservative decision to pause shipments of ELEVIDYS for non-ambulant patients while we work with the FDA to update the label and evaluate the use of an enhanced immunosuppression regimen to mitigate the risk of acute liver failure. Based on our comprehensive scientific interpretation of the data, which shows no new or changed safety signals in the ambulant patient population, we will continue to ship ELEVIDYS to the ambulant population. We look forward to continued discussions and sharing of information with FDA in order to advance our shared purpose of protecting patient safety and informed access to care. We recognize that the death of any patient is heartbreaking, including the recent death of a 51-year-old non-ambulant Limb-Girdle Muscular Dystrophy (LGMD) patient. We also want to clarify that this tragic event occurred in a Phase 1 clinical trial for an investigational gene therapy called SRP-9004. SRP-9004 is a clinical stage therapy that is intended to treat a different disease (LGMD Type 2D), is administered using a different dose, and is manufactured using a different process. The LGMD study participant who passed away was not treated with ELEVIDYS, and the dosing for the SRP-9004 trial had concluded at the time of his death. Additionally, in a timely manner, Sarepta reported this ALF event as a life-threatening case to FDA on June 20, 2025, and further followed up with notification to FDA of the death on July 3, 2025, in accordance with applicable law and our commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for individuals devastated by Duchenne, a rare, progressive and ultimately fatal disease. We are committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials, ELEVIDYS, and expected plans, including our plan to continue to ship ELEVIDYS to the ambulant population and continued discussions and sharing of information with FDA in order to advance our shared purpose of protecting patient safety and informed access to care. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; success in clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.
Business Wire
2 days ago
- Business Wire
Prime Healthcare Services, Inc. Schedules 2025 2 nd Quarter Earnings Conference Call
ONTARIO, Calif.--(BUSINESS WIRE)--Prime Healthcare Services will report earnings the morning of August 12 th, 2025, to be followed by a conference call at 2:00 p.m. (ET) to discuss the reported results. Please ensure you pre-register prior to the call by emailing EGarcia27@ to facilitate attaining your individual pin that will allow direct access to the call. Access to the call will not be available to those who have not registered in advance. For those who are unable to listen to the conference call live, there will be a replay available through September 11 th, 2025, which can be accessed by dialing (866) 583-1035 (U.S. Toll Free), passcode 4337506#. About Prime Healthcare and Prime Healthcare Foundation: Prime Healthcare is an award-winning health system operating 51 hospitals and more than 360 outpatient locations in 14 states, providing over 2.5 million patient visits annually. It is one of the nation's leading health systems, with nearly 57,000 employees and physicians. Eighteen of the Prime Healthcare hospitals are members of the Prime Healthcare Foundation, a 501(c)(3) not-for-profit public charity. Based in Ontario, California, Prime Healthcare is nationally recognized for award-winning quality care and has been named a 10 Top and 15 Top Health System by Truven Health Analytics. Its hospitals have been named among the nation's '100 Top Hospitals' 69 times is one of Healthgrades most awarded health systems in the nation for patient safety. To learn more, please visit
Business Wire
2 days ago
- Business Wire
EHC Investors Have Opportunity to Join Encompass Health Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Encompass Health Corporation ('Encompass Health' or 'the Company') (NYSE: EHC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Encompass Health is the subject of an article published by The New York Times on July 15, 2025. According to the Times, several of the Company's rehabilitation hospitals suffered incidents of fatal carbon monoxide poisoning, bed alarm failures, and medication errors. Based on this news, shares of Encompass Health fell by about 10% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
